论文部分内容阅读
目的:探讨孕妇血清和胎盘Fas/FasL系统的表达与胎儿宫内生长发育的关系。方法:35例胎儿生长受限(fetal growth restriction,FGR)患者,采用ELISA方法测定血清sFas和sFasL水平,采用Western blotting检测胎盘Fas和FasL的蛋白含量,并以45例正常孕妇为对照。结果:FGR组与对照组血清sFas水平分别为3.63±0.29 mg/L和1.17±0.53 mg/L,FGR组高于对照组(P<0.05)。FGR组胎盘组织FasL含量(0.341±0.371)与正常组(0.917±0.15)比较显著下降(P<0.05),并且FasL含量与胎盘相对重量和新生儿体质量呈显著正相关,相关系数分别为0.791和0.638。结论:FGR患者血清sFas水平升高,胎盘组织FasL下降与胎盘相对重量及新生儿体质量相关,提示母-胎界面免疫耐受异常亦可能是胎儿生长受限发病机制中的重要因素之一。
Objective: To investigate the relationship between the expression of Fas / FasL in serum and placenta of pregnant women and the growth and development of the fetus. Methods: Serum levels of sFas and sFasL were measured by ELISA in 35 patients with fetal growth restriction (FGR). The protein levels of Fas and FasL in the placenta were detected by Western blotting, and 45 normal pregnant women were used as controls. Results: The levels of serum sFas in FGR group and control group were 3.63 ± 0.29 mg / L and 1.17 ± 0.53 mg / L, respectively, and those in FGR group were higher than those in control group (P <0.05). The content of FasL in placenta of FGR group (0.341 ± 0.371) was significantly lower than that in normal group (0.917 ± 0.15) (P <0.05), and the content of FasL was positively correlated with the relative weight of placenta and neonatal body weight, the correlation coefficients were 0.791 And 0.638. CONCLUSIONS: The increase of serum sFas in FGR patients and the decrease of FasL in placenta are correlated with the relative weight of placenta and neonatal body weight. It suggests that the abnormal immune tolerance at the mother-fetus interface may also be one of the important factors in the pathogenesis of fetal growth restriction.